多替阿巴拉米片进入国家医保了吗？

Suimeike () was approved for marketing in the United States in 2014. It is currently the only three-in-one compound drug containing dolutegravir (DTG). It integrates treatment drugs for different stages of viral infection into the same tablet. Patients only need to take one drug to achieve the effect of combined medication. Moreover, oral administration greatly improves patients' medication compliance and improves their quality of life.

In January 2018, GlaxoSmithKline China announced that it was officially launched in China for the treatment of adults and adolescents over 12 years old infected with human immunodeficiency virus (HIV) weighing at least 40kg. 

Has Abalami Tablets been included in the national medical insurance?

In the Chinese mainland market, the launch of Suimeike (dolute abalamib tablets) has filled the gap in single-pill compound preparations of anti-AIDS drugs. However, at present, Suimeikai (Dolutea Abalamid Tablets) has not been included in the national medical insurance, and patients need to pay for Suimeike (Dolutea Abalamid Tablets) at their own expense. Medical Companion Travel understands that the price of Suimeikai on the market in India is relatively cheap, with a box of 30 tablets. Due to the floating exchange rate, the price is not fixed. Please consult the Medical Companion Travel Service for the specific price of Dota Abalami Tablets.

Trimax is currently the only three-in-one compound drug containing dolutegravir (DTG). Trimax (dolutegravir tablets) cannot be used for individuals who carry the HLA-B*5701 gene. Patients carrying this gene will have a high risk of severe hypersensitivity reactions (type I allergic reactions) when using Trimax. Therefore, before taking Suimeike (), you need to complete the test to determine whether you carry the special type of "HLA-B*5701" gene.

Recommended related hot articles: /newsDetail/82219.html